

## BRIEF REPORT



# Perivascular Spaces Are Associated With CSF A $\beta$ in Cerebral Amyloid Angiopathy but Not in Deep Perforator Arteriopathy

Philipp Arndt<sup>1</sup>, MD; Malte Pfister, MD; Sebastian Johannes Müller, MD; Valentina Perosa<sup>2</sup>, MD; Hendrik Mattern<sup>3</sup>, PhD; Marc Dörner<sup>4</sup>, MD; Patrick Müller, MD, PhD; Sven G. Meuth<sup>5</sup>, MD, PhD; Cornelia Garz; Katja Neumann, PhD; Jose Bernal, PhD; Stefanie Schreiber<sup>6</sup>, PhD

**BACKGROUND:** Centrum semiovale perivascular spaces (CSO PVS) are common to different cerebral small vessel disease (CSVD) subtypes, yet their enlargement to the point of visibility on magnetic resonance imaging is thought to occur through distinct mechanisms. In cerebral amyloid angiopathy (CAA), CSO PVS are thought to reflect impaired perivascular A $\beta$  (amyloid- $\beta$ ) drainage, whereas in deep perforator arteriopathy (DPA) they may result from microangiopathy-related arterial stiffening and altered fluid dynamics. The extent to which this can be confirmed in vivo remains unclear.

**METHODS:** We retrospectively analyzed 186 patients with CSVD and cerebrospinal fluid (CSF) A $\beta$  biomarkers (n=111 probable CAA, n=75 DPA). CSO PVS were counted on axial T2-weighted images. Associations between CSO PVS and CSF biomarkers were assessed via Pearson correlation and multivariable linear regression, including an interaction term between CSF A $\beta$  and CSVD subtype, adjusted for demographics and neuroimaging markers of CSVD.

**RESULTS:** Patients with higher CSO PVS counts were generally younger, had lower white matter hyperintensity burden, higher basal ganglia PVS counts, and were more frequently affected by cortical superficial siderosis. CSO PVS counts were similar in patients with CAA and DPA. The association between CSF A $\beta_{42/40}$  ratio and CSO PVS burden was observed in patients with CAA, but not in those with DPA (interaction term between CSF A $\beta_{42/40}$  ratio and CAA:  $\beta=-0.27$ ;  $P=0.016$ ), independent of demographics and other neuroimaging markers of CSVD. CSF A $\beta_{40}$  showed no association with CSO PVS counts in any model.

**CONCLUSIONS:** Our findings strengthen the pathophysiological link between CSO PVS and A $\beta$  pathology in CAA but not in DPA. These results extend previous histopathologic and neuroimaging work and underscore the need to interpret CSO PVS in the context of underlying CSVD subtype.

**GRAPHIC ABSTRACT:** A [graphic abstract](#) is available for this article.

**Key Words:** cerebral amyloid angiopathy ■ cerebrospinal fluid ■ magnetic resonance imaging ■ neuroimaging ■ siderosis

The pathological processes contributing to the enlargement and subsequent visibility of centrum semiovale perivascular spaces (CSO PVS) on magnetic resonance imaging (MRI) remain elusive. In cerebral amyloid angiopathy (CAA), where CSO PVS have supportive diagnostic value,<sup>1,2</sup> they are thought to reflect impaired perivascular clearance resulting from

progressive amyloid- $\beta$  (A $\beta$ ) deposition in cortical and leptomeningeal vessel walls.<sup>3,4</sup> However, in hypertensive arteriopathy or deep perforator arteriopathy (DPA)—disorders typically associated with hypertensive damage rather than A $\beta$  pathology<sup>5</sup>—CSO PVS are thought to be a result of an impairment of perivascular fluid transport owing to altered hemodynamics (eg, reduced vessel

Correspondence to: Philipp Arndt, MD, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany. Email [ph.ulbrich@web.de](mailto:ph.ulbrich@web.de)  
Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.053794>.

© 2026 The Authors. *Stroke* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. *Stroke* is available at [www.ahajournals.org/journal/str](http://www.ahajournals.org/journal/str)

## Nonstandard Abbreviations and Acronyms

|                            |                                |
|----------------------------|--------------------------------|
| <b>A<math>\beta</math></b> | amyloid- $\beta$               |
| <b>BG</b>                  | basal ganglia                  |
| <b>CAA</b>                 | cerebral amyloid angiopathy    |
| <b>CSF</b>                 | cerebrospinal fluid            |
| <b>CSO</b>                 | centrum semiovale              |
| <b>cSS</b>                 | cortical superficial siderosis |
| <b>CSVD</b>                | cerebral small vessel disease  |
| <b>DPA</b>                 | deep perforator arteriopathy   |
| <b>ICH</b>                 | intracerebral hemorrhage       |
| <b>MRI</b>                 | magnetic resonance imaging     |
| <b>PVS</b>                 | perivascular spaces            |
| <b>WMH</b>                 | white matter hyperintensities  |

pulsatility and increased arterial stiffness).<sup>6–8</sup> As such, CSO PVS may thus arise from distinct mechanisms across cerebral small vessel disease (CSVD) subtypes, including microvascular degeneration, blood–brain barrier dysfunction, or other age-related changes.<sup>9</sup> Whether CSO PVS consistently relates to A $\beta$  pathology or differs between CAA and DPA remains unresolved.

In this study, we examined associations between CSO PVS burden and cerebrospinal fluid (CSF) A $\beta$  biomarkers in a clinical cohort of 186 patients with probable CAA or DPA. Using an interaction model, we tested whether the association between CSO PVS and CSF A $\beta$  differs by CSVD subtype, hypothesizing that CSO PVS reflects impaired A $\beta$  clearance in CAA but not in DPA.

## METHODS

### Data Availability

The corresponding author has full access to the data used in this article, and all data are available on reasonable request. See the [Supplemental Material](#) for the STROBE guidelines checklist (Strengthening the Reporting of Observational Studies in Epidemiology) required by the journal.

### Study Design and Participants

We retrieved imaging, clinical, and biomarker data from patients with MRI-confirmed hemorrhagic CSVD markers and available CSF A $\beta$  biomarker data from our prospectively maintained CSVD database (2010–2024) at the Department of Neurology, University Hospital Magdeburg.<sup>5</sup> According to the Standards for Reporting Vascular Changes on Neuroimaging and the Boston criteria v2.0,<sup>1,10</sup> n=186 patients were classified as probable CAA or DPA. The local ethics committee (No.331 07/2017, addendum 11/2021) approved this study.

### Cerebrospinal Fluid

CSF sampling was performed as part of routine clinical workup in patients with cognitive symptoms, atypical imaging findings,

or suspected neurodegenerative copathology. Samples were centrifuged at 4°C, aliquoted, and stored at –80°C until analysis. Biomarker levels were determined using ELISA kits (n=133; until 12/2019: Innostest, Innogenetics, Ghent, Belgium) or automated immunoassays (n=53; LUMIPULSE G600 II, Fujirebio Inc, Japan, from 01/2020). To account for methodological variability between assay platforms, CSF A $\beta$  biomarker values were standardized using z-transformation within each assay group, ensuring comparability across methods. Each transformed value reflects the number of SD from the group mean. Thresholds were 0.050 for the A $\beta_{42/40}$  ratio, 70 pg/mL for pTau using ELISA kits, and 0.069 for the A $\beta_{42/40}$  ratio, 56 pg/mL for pTau using immunoassays.

### MRI Acquisition and Analysis

Clinical 3T (n=90, Skyra) or 1.5T (n=96, Sola) MRI scans (Siemens Healthineers) were used to rate cortical superficial siderosis (cSS), microbleeds, white matter hyperintensities (WMH), lacunes, and PVS using Standards for Reporting Vascular Changes on Neuroimaging criteria.<sup>10</sup> A trained investigator (M.P), blinded to CSF results, assessed cSS and microbleeds on T2\*-weighted GRE, WMH and lacunes on T2-weighted fluid-attenuated inversion recovery, and PVS on axial T2-weighted TSE. Microbleeds and lacunes were rated using the Microbleed Anatomic Rating Scale,<sup>11</sup> WMH using the Fazekas scale, specific WMH patterns as recently proposed,<sup>12,13</sup> and cSS using the Boston 2.0 criteria.<sup>1</sup> CSO and basal ganglia (BG) PVS were quantified as absolute counts on axial T2-weighted images. Continuous counts were chosen over semi-quantitative scores to enhance statistical sensitivity and model variance. A high degree of PVS represents counts of PVS >20 in 1 hemisphere in either BG or CSO. The presence of deep microbleeds defined DPA.

To assess interrater reliability of PVS quantification, n=40 randomly selected MRIs were independently re-rated by a certified senior neuroradiologist (S.J.M.), blinded to the initial ratings. Interrater agreement was good for both regions (CSO: ICC, 0.79 [95% CI, 0.64–0.88]; BG: ICC, 0.75 [95% CI, 0.45–0.88]).

### Statistical Analysis

Results of continuous variables were expressed as median (interquartile range) or mean (SD), and categorical variables were expressed as proportions.

#### Univariate Analysis

Group comparisons were performed in univariate analyses, using the  $\chi^2$  test, 2-sample *t* test, or Mann-Whitney *U* test. Pearson correlation was used to exploratively assess associations between CSO PVS and (1) CSF A $\beta_{42/40}$  ratio as a marker of parenchymal A $\beta$  and (2) CSF A $\beta_{40}$  as a marker of vascular A $\beta$  in CAA and DPA groups separately.

#### Moderation Analysis

To test whether the association between CSF A $\beta_{42/40}$  ratio and CSO PVS counts differed by CSVD subtype (CAA versus DPA), moderation analysis was performed using multivariable linear regression. Models included an interaction term (A $\beta_{42/40}$  ratio  $\times$  CSVD subtype) and were adjusted for age, sex, lobar microbleeds, cSS, WMH Fazekas scores, and BG PVS

counts. CSVD subtype was coded as a binary variable (0=DPA, 1=CAA). All predictors were entered simultaneously based on prior pathophysiological relevance. Statistical significance was defined as  $P < 0.05$  (SPSS v24).

## RESULTS

Among 186 patients (median age, 75 years [interquartile range, 67–80]; 41% female), 111 were classified as probable CAA and 75 as DPA. Patients' clinical characteristics included most frequently cognitive impairment ( $n=101$ , 54%), history of ischemic stroke ( $n=61$ , 33%), gait disturbances ( $n=55$ , 30%), cerebral hemorrhage, that is, intracerebral hemorrhage (ICH) or convexity subarachnoid hemorrhage ( $n=54$ , 30%;  $n=33$  with probable CAA and  $n=21$  with DPA), and seizure ( $n=42$ , 23%). Patients with CAA were significantly older ( $P < 0.001$ ) and had lower CSF A $\beta_{42/40}$  ratio levels ( $P < 0.001$ ) compared with DPA. CSF A $\beta_{40}$  ( $P=0.297$ ) and CSO PVS counts ( $P=0.413$ ) were, nonetheless, similar between groups (Table 1).

### Univariate Analysis

Patients with higher CSO PVS counts had lower CSF A $\beta_{42/40}$  ratios ( $r=-0.148$ ,  $P=0.049$ ). This association was primarily driven by patients with CAA ( $r=-0.265$ ,  $P=0.005$ ) and not by those with DPA, according to subsequent group analyses. No association between CSO PVS counts and CSF A $\beta_{40}$  was observed (Figure).

### Multivariate and Moderation Analysis

Patients with higher CSO PVS counts were younger ( $\beta=-0.26$ ,  $P=0.004$ ), had lower WMH scores ( $\beta=-0.24$ ,  $P=0.002$ ) but higher BG PVS counts ( $\beta=0.17$ ,  $P=0.027$ ), and were more likely to have cSS ( $\beta=0.21$ ,  $P=0.004$ ; Table 2). The association between CSF A $\beta_{42/40}$  ratio and CSO PVS burden was present in patients with CAA but not those with DPA (interaction term  $\beta=-0.27$ ,  $P=0.016$ ), independent of age, sex, lobar microbleeds, cSS, WMH burden, BG PVS, and AD pathology. Subgroup analyses revealed that this association was primarily driven by patients without cerebral hemorrhage ( $n=132$ , interaction term  $P=0.010$ ) as opposed to those with it ( $n=54$  with ICH or subarachnoid hemorrhage, interaction term  $P=0.962$ ). Replacing A $\beta_{42/40}$  with A $\beta_{40}$  made both the main effect ( $P=0.580$ ) and the interaction with CSVD subtype ( $P=0.930$ ) nonsignificant, suggesting that CSO PVS burden relates specifically to the A $\beta_{42/40}$  ratio.

## DISCUSSION

The relationship between CSF A $\beta_{42/40}$  ratio and CSO PVS burden differed by CSVD subtype: lower A $\beta_{42/40}$  levels were linked to higher CSO PVS counts in patients

**Table 1. Intergroup Comparison of Patient Characteristics**


| Characteristics                   | DPA, n=75    | Probable CAA, n=111 | Statistical analysis           |
|-----------------------------------|--------------|---------------------|--------------------------------|
| Age                               | 70 (60–78)   | 76 (72–81)          | $Z=-4.4$ , $P < 0.001^*$       |
| Female sex                        | 31 (41%)     | 45 (41%)            | $\chi^2=0.0$ , $P=0.914$       |
| Hypertension                      | 68/72 (94%)  | 90/103 (87%)        | $\chi^2=2.4$ , $P=0.120$       |
| Dyslipidemia                      | 35/72 (49%)  | 41/103 (40%)        | $\chi^2=1.3$ , $P=0.248$       |
| Type 2 diabetes                   | 18/72 (25%)  | 33/103 (32%)        | $\chi^2=1.0$ , $P=0.313$       |
| Lobar ICH on MRI                  | 11 (15%)     | 27 (24%)            | $\chi^2=2.6$ , $P=0.109$       |
| Deep ICH on MRI                   | 4 (5%)       | 0 (0%)              | $\chi^2=6.1$ , $P=0.049^*$     |
| Presence of cSS                   | 11 (15%)     | 22 (20%)            | $\chi^2=0.8$ , $P=0.367$       |
| Number of lobar CMB               | 7 (3–20)     | 5 (2–18)            | $Z=0.5$ , $P=0.648$            |
| Number of deep CMB                | 3 (1–6)      | 0 (0–0)             | $Z=13.0$ , $P < 0.001^*$       |
| Presence of lobar lacune          | 33 (44%)     | 33 (30%)            | $\chi^2=3.8$ , $P=0.051$       |
| Presence of a deep lacuna         | 31 (41%)     | 24 (21%)            | $\chi^2=9.0$ , $P=0.003^*$     |
| WMH Fazekas scale                 | 6 (4–6)      | 5 (4–6)             | $Z=1.9$ , $P=0.063$            |
| High-degree BG PVS                | 43 (57%)     | 34 (31%)            | $\chi^2=13.2$ , $P < 0.001^*$  |
| BG PVS counts                     | 26 (13)      | 19 (11)             | $T=3.9$ , $P < 0.001$          |
| High-degree CSO PVS               | 71 (95%)     | 102 (92%)           | $\chi^2=0.5$ , $P=0.467$       |
| CSO PVS counts                    | 36 (8)       | 37 (11)             | $T=0.8$ , $P=0.413$            |
| CSF amyloid pathology (A+)        | 10 (13%)     | 52 (47%)            | $\chi^2=22.6$ , $P < 0.001^*$  |
| CSF AD pathology (A+T+)           | 2 (3%)       | 32 (29%)            | $\chi^2=20.51$ , $P < 0.001^*$ |
| A $\beta_{42/40}$ ratio (z-score) | 0.45 (1.02)  | -0.31 (0.86)        | $T=5.5$ , $P < 0.001^*$        |
| A $\beta_{1-40}$ (z-score)        | -0.09 (0.90) | 0.06 (1.05)         | $T=-1.0$ , $P=0.297$           |

Data are represented as median (interquartile range), mean (SD), or  $n$  (%). AD indicates Alzheimer disease; A $\beta$ , beta-amyloid; BG, basal ganglia; CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; CSF, cerebrospinal fluid; CSO, centrum semiovale; cSS, cortical superficial siderosis; CSVD, cerebral small vessel disease; DPA, deep perforator arteriopathy; ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; PVS, perivascular spaces; and WMH, white matter hyperintensities.

\*Significant  $P$  values.

with probable CAA, but not in those with DPA. This association persisted after adjustment for demographics, AD pathology, and other CSVD imaging markers, supporting the notion that CSO PVS may serve as an amyloid-specific structural biomarker of CAA.

Brain autopsies of patients with verified CAA have shown that CSO PVS were associated with overlying cortical CAA severity.<sup>3</sup> This aligns with our in vivo finding since lower CSF A $\beta_{42/40}$  ratio levels reflect advanced amyloid retention. Interestingly, we observed no association between CSO PVS burden and CSF A $\beta_{40}$ . Although A $\beta_{40}$  aggregates in CAA-affected vessels and CSF A $\beta_{40}$  levels are reduced in CAA compared with controls and AD,<sup>14</sup> its diagnostic performance is limited.<sup>14–16</sup> This limitation is attributable to substantial interindividual



**Figure. Scatterplots.**

Scatterplots showing associations between centrum semiovale perivascular space counts and cerebrospinal fluid (CSF) amyloid- $\beta$  biomarkers in cerebral amyloid angiopathy (CAA; **A–C**) and deep perforator arteriopathy (DPA; **D–F**). In CAA, CSO PVS were negatively correlated with CSF A $\beta_{42/40}$  ratio (**B**) but not A $\beta_{40}$  (**E**). In DPA, no significant associations were observed between CSO PVS and A $\beta$  biomarkers (**C** and **F**). Each dot represents an individual patient. Regression lines represent linear fit with 95% CIs.

variability and the fact that CSF A $\beta_{40}$  primarily reflects overall A $\beta$  production rather than clearance impairment. Accordingly, A $\beta_{40}$  is mainly used to normalize A $\beta_{42}$  levels, yielding the A $\beta_{42/40}$  ratio as a robust marker of amyloid retention. A contribution of parenchymal plaque pathology cannot be entirely excluded.

Past neuroimaging studies have demonstrated that high-degree CSO PVS are more frequent in CAA-related ICH (46%) compared with deep hemorrhages (19%).<sup>2,17</sup> Mixed location hemorrhages reflect advanced arteriolosclerotic CSVD, and in mixed location ICH, high-degree CSO PVS (28%) was more frequent compared with deep ICH (15%),<sup>18,19</sup> showing that CAA-independent mechanisms drive CSO PVS enlargement as well. Interestingly, age and BG PVS were strong predictors. This indicates that there are age-dependent pathomechanisms leading to brain-wide PVS enlargement. A possible interpretation of this result is that the 2 most common sporadic CSVD types (CAA and arteriolosclerosis) both contribute to glymphatic failure and interstitial fluid accumulation.<sup>9</sup>

CSO PVS counts were higher in younger individuals and in those with higher BG PVS counts and lower WMH burden. While WMH and PVS are known to interact and

may develop in spatial proximity,<sup>20,21</sup> our cohort included patients with advanced white matter disease, in whom extensive WMH may limit reliable PVS quantification. This issue has also been noted as a limitation and potential confounder in computational segmentation studies.<sup>22</sup> The positive association between BG and CSO PVS supports the concept of global mechanisms that affect perivascular fluid drainage across brain regions. Brain atrophy represents an additional potential confounder, as age-related tissue loss may influence the apparent visibility of PVS, and PVS counts are not normalized to tissue volume. Taken together, these findings underscore the need for further studies addressing the interplay between vascular pathology, neurodegeneration, and perivascular space enlargement.

Previous large-scale studies across diverse Alzheimer disease cohorts have reported weak or absent associations between CSO PVS and A $\beta$  biomarkers.<sup>21,23–25</sup> This inconsistency may be attributed to heterogeneous patient populations and the multifactorial nature of PVS enlargement across disease states. In contrast, smaller PET-based studies focused on CAA have demonstrated a robust link between CSO PVS burden and (vascular)

**Table 2. Multivariable Linear Regression Model Examining the Association Between CSO PVS Counts and CSF A $\beta$  Biomarkers in Patients With CSVD**

| Independent variable                       | B (SE)       | Beta  | P value |
|--|--------------|-------|---------|
| Age  | −0.28 (0.09) | −0.26 | 0.004*  |
| Female                                     | 0.92 (1.46)  | 0.05  | 0.529   |
| CSVD type (CAA)                            | 2.02 (1.71)  | 0.10  | 0.239   |
| CSF A $\beta_{42/40}$                      | −0.24 (1.20) | −0.03 | 0.839   |
| CSF A $\beta_{42/40}$ × CSVD type          | −3.95 (1.62) | −0.27 | 0.016*  |
| Lobar microbleed counts                    | 0.01 (0.01)  | 0.06  | 0.418   |
| Presence of cortical superficial siderosis | 5.56(1.91)   | 0.21  | 0.004*  |
| WMH Fazekas scale                          | −1.73 (0.54) | −0.24 | 0.002*  |
| Basal ganglia PVS counts                   | 0.14 (0.06)  | 0.17  | 0.027*  |
| CSF AD pathology (A+T+)                    | −1.82 (2.21) | −0.07 | 0.412   |

The model included CSO PVS as the dependent variable and was adjusted for age, sex, number of lobar microbleeds, presence of cortical superficial siderosis, total WMH Fazekas scale, and CSF AD pathology. AD indicates Alzheimer disease; A $\beta$ , beta-amyloid; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fluid; CSO, centrum semiovale; CSVD, cerebral small vessel disease; PVS, perivascular spaces; and WMH, white matter hyperintensities.

\*Significant *P* values.

A $\beta$  deposition.<sup>4,26,27</sup> Our findings validate these associations in a larger, well-defined CAA cohort using CSF biomarkers, supporting the view that in CAA, CSO PVS are a structural correlate of impaired perivascular A $\beta$  clearance, independent of demographics and other neuroimaging markers of CAA. This supports their utility as a non-hemorrhagic imaging biomarker of CAA, complementing other Boston criteria version 2.0 features.

## Limitations

The retrospective and cross-sectional design precludes causal inference. CSF biomarker data were obtained using different assay platforms over time, requiring standardization. The focus of our study—the differential association between CSO PVS burden and CSF A $\beta$  biomarkers across CSVD subtypes—constrained our analysis to individuals with available CSF samples. As CSF testing is not routinely performed in CAA or DPA, our cohort may be enriched for cognitively impaired CSVD patients and may underrepresent individuals presenting with acute cerebral hemorrhage. Further, DPA patients with asymptomatic disease stages or lacunar stroke without microbleeds and without cognitive involvement may follow different pathophysiological trajectories and were underrepresented as well, limiting extrapolation to the full DPA spectrum. Replication in unselected or population-based CAA and DPA cohorts should therefore be undertaken in the future. In addition, CSO PVS were assessed via visual counts rather than automated volumetric segmentation, which may limit reproducibility. MRI scans were acquired across clinically diverse protocols and platforms, which could introduce variability in image

resolution and contrast. However, as PVS were quantified on the single axial T2-weighted slice demonstrating the highest PVS burden, the impact of variability of slice thickness is reduced. Consistent rating procedures, good interrater reliability, and blinded assessments further mitigate these concerns.

## Conclusions

Our findings reinforce that CSO PVS are not uniform imaging markers of small vessel disease but exhibit subtype-specific relationships with amyloid pathology. The association with CSF A $\beta_{42/40}$  ratio was specific to CAA and absent in DPA, supporting differential underlying pathophysiological mechanisms. These results extend previous histopathologic and neuroimaging work and underscore the need to interpret CSO PVS in the context of underlying CSVD subtype. Although not causal, the observed associations suggest that CSO PVS may hold distinct diagnostic and pathophysiological relevance depending on the vascular phenotype. Future studies using automated PVS quantification, longitudinal follow-up, and structural imaging metrics such as atrophy will help define their utility as imaging biomarkers across the CSVD spectrum.

## ARTICLE INFORMATION

Received September 16, 2025; final revision received January 28, 2026; accepted February 13, 2026.

### Affiliations

Department of Neurology (P.A., M.P., C.G., K.N., S.S.), Department of Neuroradiology (S.J.M.), and Department of Cardiology (P.M.), Otto-von-Guericke University, Magdeburg, Germany. German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Magdeburg (P.A., H.M., M.D., C.G., J.B., S.S.). J. Philip Kistler Stroke Research Center, Massachusetts General Hospital/Harvard Medical School, Boston (V.P.). Biomedical Magnetic Resonance, Faculty of Natural Sciences, Otto-von-Guericke University, Magdeburg, Germany (H.M.). Center for Clinical Brain Sciences, the University of Edinburgh, United Kingdom (J.B., S.S.). Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine (M.D.) and Department of Neurology (M.D.), University Hospital Zurich, University of Zurich, Switzerland. German Center for Mental Health (DZPG), Magdeburg (P.M., S.S.). Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany (S.G.M.). Department of Artificial Intelligence in Biomedical Engineering (AIBE), Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Germany (J.B.).

### Author Contributions

Dr Schreiber contributed to the conception and design of the study; Drs S.J. Müller, Pfister, P. Müller, and Garz contributed to the acquisition and analysis of data; Drs Arndt, Bernal, and Schreiber contributed to drafting the text; Dr Arndt contributed to preparing the figures and tables. All the authors contributed to a critical review of the article.

### Sources of Funding

Dr Bernal was supported by The Galen and Hilary Weston Foundation under the Novel Biomarkers 2019 scheme (ref UB190097) administered by the Weston Brain Institute and the Row Fogo Charitable Trust (ref no. BRO-D. FID3668413).

### Disclosures

Prof Meuth reports compensation for other services from Alexion Pharmaceuticals, Janssen Pharmaceuticals, Ono Pharmaceuticals, Sanofi Genzyme, Hexal AG, Amicus Therapeutics, Springer, BioNTech, UCB, Stada, Teva Pharmaceutical Industries, Celgene, Bayer Healthcare, Mylan, Novartis, Almirall, Merck, Roche, Biogen, and Viatrix. The other authors report no conflicts.

## REFERENCES

- Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albuquer JF, Banerjee G, Barbato C, Bonneville F, Brandner S, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. *Lancet Neurol*. 2022;21:714–725. doi: 10.1016/S1474-4422(22)00208-3
- Charidimou A, Boulouis G, Pasi M, Auriel E, van Etten ES, Haley K, Ayres A, Schwab KM, Martinez-Ramirez S, Goldstein JN, et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. *Neurology*. 2017;88:1157–1164. doi: 10.1212/WNL.0000000000003746
- Perosa V, Oltmer J, Munting LP, Freeze WM, Auger CA, Scherlek AA, van der Kouwe AJ, Iglesias JE, Atzeni A, Bacskaï BJ, et al. Perivascular space dilation is associated with vascular amyloid- $\beta$  accumulation in the overlying cortex. *Acta Neuropathol*. 2022;143:331–348. doi: 10.1007/s00401-021-02393-1
- Charidimou A, Hong YT, Jäger HR, Fox Z, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, Werring DJ, Baron JC. White matter perivascular spaces on magnetic resonance imaging: marker of cerebrovascular amyloid burden? *Stroke*. 2015;46:1707–1709. doi: 10.1161/STROKEAHA.115.009090
- Arndt P, Pfister M, Perosa V, Mattern H, Bernal J, John A-C, Dörner M, Müller P, Braun-Dullaeus RC, Garz C, et al. Risk factors and clinical significance of neurodegenerative co-pathologies in symptomatic cerebral small vessel disease. *J Neurol*. 2025;272:349. doi: 10.1007/s00415-025-13087-z
- Mestre H, Tithof J, Du T, Song W, Peng W, Sweeney AM, Olveda G, Thomas JH, Nedergaard M, Kelley DH. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. *Nat Commun*. 2018;9:4878. doi: 10.1038/s41467-018-07318-3
- Spence JD. Blood pressure gradients in the brain: their importance to understanding pathogenesis of cerebral small vessel disease. *Brain Sci*. 2019;9:21. doi: 10.3390/brainsci9020021
- Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, Csizsar A. Hypertension-induced cognitive impairment: from pathophysiology to public health. *Nat Rev Nephrol*. 2021;17:639–654. doi: 10.1038/s41581-021-00430-6
- Perosa V, Oltmer J, Bax F, van den Berg ML, Auger CA, Rotta J, Perbet R, Augustinack J, Frosch MP, Connors T, et al. Relationship between cerebral small vessel disease and proteinopathies in the elderly temporal lobe. *Acta Neuropathol Commun*. 2025;13:156. doi: 10.1186/s40478-025-02076-y
- Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al; Standards for Reporting Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822–838. doi: 10.1016/S1474-4422(13)70124-8
- Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, Werring DJ. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology*. 2009;73:1759–1766. doi: 10.1212/WNL.0b013e3181c34a7d
- Charidimou A, Boulouis G, Haley K, Auriel E, van Etten ES, Fotiadis P, Reijmer Y, Ayres A, Vashkevich A, Dipucchio ZY, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. *Neurology*. 2016;86:505–511. doi: 10.1212/WNL.0000000000002362
- Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, et al; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke*. 2001;32:1318–1322. doi: 10.1161/01.str.32.6.1318
- Charidimou A, Boulouis G. Core CSF biomarker profile in cerebral amyloid angiopathy: updated meta-analysis. *Neurology*. 2024;103:e209795. doi: 10.1212/WNL.000000000000209795
- Margraf NG, Jensen-Kondering U, Weiler C, Leyboldt F, Maetzler W, Philippen S, Bartsch T, Flüh C, Röcken C, Möller B, et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: new data and quantitative meta-analysis. *Front Aging Neurosci*. 2022;14:783996. doi: 10.3389/fnagi.2022.783996
- Xu F, Fu Z, Dass S, Kotarba AE, Davis J, Smith SO, van Nostrand WE. Cerebral vascular amyloid seeds drive amyloid  $\beta$ -protein fibril assembly with a distinct anti-parallel structure. *Nat Commun*. 2016;7:13527. doi: 10.1038/ncomms13527
- Pasi M, Sugita L, Xiong L, Charidimou A, Boulouis G, Pongpitakmetha T, Singh S, Kourkoulis C, Schwab K, Greenberg SM, et al. Association of cerebral small vessel disease and cognitive decline after intracerebral hemorrhage. *Neurology*. 2021;96:e182–e192. doi: 10.1212/WNL.00000000000011050
- Scheumann V, Schreiber F, Perosa V, Assmann A, Mawrin C, Garz C, Heinze H-J, Görtler M, Düzel E, Vielhaber S, et al. MRI phenotyping of underlying cerebral small vessel disease in mixed hemorrhage patients. *J Neurol Sci*. 2020;419:117173. doi: 10.1016/j.jns.2020.117173
- Pasi M, Charidimou A, Boulouis G, Auriel E, Ayres A, Schwab KM, Goldstein JN, Rosand J, Viswanathan A, Pantoni L, et al. Mixed-location cerebral hemorrhage/microbleeds: underlying microangiopathy and recurrence risk. *Neurology*. 2018;90:e119–e126. doi: 10.1212/WNL.0000000000004797
- Barnes A, Ballerini L, Del Valdés Hernández MC, Chappell FM, Muñoz Maniega S, Meijboom R, Backhouse EV, Stringer MS, Duarte Coello R, Brown R, et al. Topological relationships between perivascular spaces and progression of white matter hyperintensities: a pilot study in a sample of the Lothian Birth Cohort 1936. *Front Neurol*. 2022;13:889884. doi: 10.3389/fneur.2022.889884
- Menze I, Bernal J, Kaya P, Aki C, Pfister M, Geisendorfer J, Yakupov R, Coello RD, Valdés-Hernández MDC, Heneka MT, et al. Perivascular space enlargement accelerates ageing and Alzheimer's disease pathology: evidence from a three-year longitudinal multicentre study. *Alzheimers Res Ther*. 2024;16:242. doi: 10.1186/s13195-024-01603-8
- Waymont JMJ, Del Valdés Hernández MC, Bernal J, Duarte Coello R, Brown R, Chappell FM, Ballerini L, Wardlaw JM. Systematic review and meta-analysis of automated methods for quantifying enlarged perivascular spaces in the brain. *Neuroimage*. 2024;297:120685. doi: 10.1016/j.neuroimage.2024.120685
- Gertje EC, van Westen D, Panizo C, Mattsson-Carlgen N, Hansson O. Association of enlarged perivascular spaces and measures of small vessel and Alzheimer Disease. *Neurology*. 2021;96:e193–e202. doi: 10.1212/WNL.00000000000011046
- Jeong SH, Cha J, Park M, Jung JH, Ye BS, Sohn YH, Chung SJ, Lee PH. Association of enlarged perivascular spaces with amyloid burden and cognitive decline in Alzheimer Disease Continuum. *Neurology*. 2022;99:e1791–e1802. doi: 10.1212/WNL.000000000000200989
- Costa AS, Exalto LG, van der Flier WM, Teunissen CE, Barkhof F, Kuijff HJ, Biessels GJ; TRACE-VCI Study Group. Markers of amyloid- $\beta$  deposition and burden of enlarged perivascular spaces in patients with cognitive impairment and small vessel disease. *J Alzheimers Dis*. 2024;102:981–986. doi: 10.1177/1387287241296012
- Raposo N, Planton M, Payoux P, Pèran P, Albuquer JF, Calviere L, Viguier A, Rousseau V, Hitzel A, Chollet F, et al. Enlarged perivascular spaces and florbetapir uptake in patients with intracerebral hemorrhage. *Eur J Nucl Med Mol Imaging*. 2019;46:2339–2347. doi: 10.1007/s00259-019-04441-1
- Tsai HH, Pasi M, Tsai LK, Huang CC, Chen YF, Lee BC, Yen RF, Guro ME, Jeng JS. Centrum semiovale perivascular space and amyloid deposition in spontaneous intracerebral hemorrhage. *Stroke*. 2021;52:2356–2362. doi: 10.1161/STROKEAHA.120.032139